Ewha Womans University Medical Center
Ewha Womans University Medical Center
Corea del Sud, Seul
Paik Nam-sun
47 anni di esperienza
accreditamenti :
Clinica certificata da :
| Corea del Sud | Turchia | Austria | |
| Trattamento sintomatico | - | da $300 | da $700 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Malattia policistica renale. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Malattia policistica renale e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Malattia policistica renale.
Dr. Lee Chun-Yong is a urologist (MD, PhD). He is Honorary Director at Naeun Hospital and Honorary Professor at Hanyang University. He previously served as Director of Hanyang University Hospital and as Chair Professor and Head of Urology at Hanyang University College of Medicine.
His clinical focus includes urolithiasis (extracorporeal shock wave lithotripsy), prostate diseases (BPH, cancer, prostatitis), sexual dysfunction, vasectomy, cystitis, urinary incontinence, and voiding disorders.
Key roles and honors include Past and Honorary President of the Korean Endourological Society, Council Member of the International Urological Association, Visiting Scholar at UCLA, and Visiting Professor at the University of Tübingen. He was featured twice on EBS "Medical Experts". He received the Order of Civil Merit (Okjo Medal).
Il medico è un esperto di cancro al seno leader in Corea del Sud ed è riconosciuto tra i 100 migliori chirurghi al mondo per il cancro gastrico e al seno. Il medico ha introdotto la chirurgia conservativa del seno in Corea del Sud nel 1986 e ha inventato un intervento chirurgico unico per il cancro allo stomaco che minimizza il rischio di malattia da reflusso gastroesofageo. Attualmente, il medico dirige il Centro per il Cancro delle Donne presso il Centro Medico dell'Università Ewha Womans e ha precedentemente ricoperto il ruolo di Presidente dell'Ospedale Universitario Konkuk e Direttore dell'Ospedale del Centro per il Cancro della Corea. Il medico è anche un ricercatore attivo nella diagnosi e gestione del cancro al seno.<\/p>
Tolvaptan is available in South Korea for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The Ministry of Food and Drug Safety approved it in 2015. National Health Insurance has covered this medication since 2019 for specific adult patients with rapid disease progression.
Bookimed Expert Insight: South Korea is a leader in medical digitalization. Centers like Seoul National University Bundang Hospital use the BESTcare system to track drug titration. This digital monitoring is vital for Tolvaptan. It ensures precise dosing and safety for patients with fluctuating renal function.
Patient Consensus: While international discussions often focus on high costs, patients in Korea benefit from national insurance coverage. Many emphasize the need for strict adherence to the monthly blood test schedule required by local regulations.
Asan Medical Center, Seoul National University Hospital, and Severance Hospital are the premier facilities for polycystic kidney disease and transplants. These JCI-accredited institutions report transplant success rates up to 98%. They utilize advanced robotic systems and multidisciplinary teams for complex inherited conditions.
Bookimed Expert Insight: Patient volume is a primary indicator of quality in Seoul. Asan Medical Center treats 11,800 outpatients daily and manages 45% of Korea's heart transplants. This high volume across all organ categories ensures surgeons maintain peak proficiency for complex multi-organ cases often seen in advanced polycystic kidney disease.
Patient Consensus: Patients emphasize the need to start the Korean Organ Transplantation Registry paperwork early. Those who chose Asan Medical Center specifically praised the experienced surgeons and dedicated support for international patients.
South Korea offers sophisticated non-surgical management for polycystic kidney disease through Tolvaptan medication and clinical research. Major Seoul-based medical centers provide access to phase 4 pharmacological trials and innovative arterial stem cell therapies. Most protocols focus on slowing cyst growth and preserving organ function.
Bookimed Expert Insight: Korea is a leader in digitalized medicine which significantly improves safety during longitudinal PKD care. Seoul National University Bundang Hospital was the first digital hospital globally. Their BESTcare system uses AI to analyze EHRs and track progression. This digital focus helps doctors identify small changes in cyst volume faster than traditional manual reviews.
Patient Consensus: Patients note it's important that international clinics in Seoul provide personalized coordination. Many find that having experts handle translations and appointments makes specialized pharmacological therapy much easier to manage.